Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 79 |
| Active Pipeline (Recruiting Now) | 27 (9) |
| Completed vs Stopped Early | 8 / 8 (10.1%) |
| Median Closed Actual Enrollment | 192 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 4 |
| China-Japan Friendship Hospital | Beijing, Beijing Municipality | 3 |
| West China Hospital of Sichuan University | Chengdu, Sichuan | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04927481 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the CSPC ZhongQi Pharmaceutical Technology Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.